Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia

Muhamed Baljevic, MD, Bogdan Dumitriu, MD, Ju-Whei Lee, PhD, Elisabeth Paietta, PhD, Janis Racevskis, Christina Chen, BS, Eytan M. Stein, Robert E Gallagher, MD, Jacob M. Rowe, MD, Frederick R. Appelbaum, MD, Bayard L. Powell, MD, Richard A. Larson, Neal S. Young, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 2375.

https://doi.org/10.1182/blood.V124.21.2375.2375

Published: 2014

Journal Articles

Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study

Blood (2013) 122 (21): 2586.

https://doi.org/10.1182/blood.V122.21.2586.2586

Published: 2013

Journal Articles

Aberrant Expression of the MLL5 , BAALC , ID1 , and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study

Blood (2012) 120 (21): 1407.

https://doi.org/10.1182/blood.V120.21.1407.1407

Published: 2012

Journal Articles

Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

Bayard L. Powell, MD, Barry K Moser, Ph.D., Wendy Stock, MD, Robert E. Gallagher, MD, Cheryl L Willman, MD, Richard M. Stone, MD, Jacob M. Rowe, MD, Steven E. Coutre, MD, James H. Feusner, M.D., John Gregory, MD, Stephen Couban, MD, FRCPC, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Richard A. Larson, MD

Blood (2011) 118 (21): 258.

https://doi.org/10.1182/blood.V118.21.258.258

Published: 2011

Journal Articles

Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,

Ana Paula Alencar de Lima Lange, Ana Sílvia Gouvea Lima, Rafael Henriques Jacomo, Raul AM Melo, Rosane Bittencourt, MD, Ricardo Pasquini, MD, Katia B. Pagnano, MD, Evandro Fagundes, Maria de Lourdes L. F. Chauffaille, MD, PhD, Carlos S Chiattone, MD, PhD, Robert E. Gallagher, MD, Bob Lowenberg, MD, PhD, Raul Ribeiro, MD, Francesco Lo-Coco, MD, David Grimwade, PhD, Miguel A. Sanz, MD, PhD, Eduardo M. Rego, M.D., Ph.D

Blood (2011) 118 (21): 3552.

https://doi.org/10.1182/blood.V118.21.3552.3552

Published: 2011

Journal Articles

ΔNp73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,

Blood (2011) 118 (21): 3536.

https://doi.org/10.1182/blood.V118.21.3536.3536

Published: 2011

Journal Articles

Design, Synthesis and Biological Evaluation of A Boron Containing Retinoid As a Novel Therapeutic Agent for Acute Promyelocytic Leukemia

Carolina D. Schinke, MD, Bhaskar C Das, Swati Goel, Tushar Bhagat, Sangeeta Nischal, Ph.D., Saverio Minucci, George Kabalka, B.S, PhD, Robert E. Gallagher, MD, Todd Evans, PhD, Leonidas C Platanias, MD, PhD, Amit Verma, MD

Blood (2011) 118 (21): 5008.

https://doi.org/10.1182/blood.V118.21.5008.5008

Published: 2011

Journal Articles

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

Blood (2010) 116 (21): 851.

https://doi.org/10.1182/blood.V116.21.851.851

Published: 2010

Journal Articles

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.

Blood (2010) 116 (21): 1038.

https://doi.org/10.1182/blood.V116.21.1038.1038

Published: 2010

Journal Articles

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Steven D. Gore, MD, Lawrence Morris, MD, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Mikkael A. Sekeres, MD, MS, Robert J. Arceci, MD, PhD, Robert L. Redner, MD, Tianna Dauses, BSN, Esther L Schachter-Tokarz, Ibitayo Owoeye, MD, Robert E. Gallagher, MD

Blood (2008) 112 (11): 1932.

https://doi.org/10.1182/blood.V112.11.1932.1932

Published: 2008

Journal Articles

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Robert E Gallagher, MD, Esther L Schachter- Tokarz, BA, Lawrence E. Morris, Tianna Dauses, BSN, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Robert L. Redner, MD, Mikkael A. Sekeres, MD, MS, Ibitayo Owoeye, MD, Steven D. Gore, MD

Blood (2008) 112 (11): 1502.

https://doi.org/10.1182/blood.V112.11.1502.1502

Published: 2008

Journal Articles

Increased Global Gene Promoter Methylation after Relapse (Rel) of Acute Promyelocytic Leukemia (APL) from All- trans Retinoic Acid (ATRA)-Containing Treatment Is Dissociated from Concurrent Gene Expression Changes.

Da-Cheng Zhou, MD, PhD, Qingping Cui, PhD, Haesook Kim, PhD, Reid Thompson, BS, John Greally, MD, PhD, Eric E. Bouhassira, PhD, Robert E. Gallagher, MD

Blood (2007) 110 (11): 2121.

https://doi.org/10.1182/blood.V110.11.2121.2121

Published: 2007

Journal Articles

Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL).

Qingping Cui, PhD, Haesook Kim, PhD, Da-Cheng Zhou, MD,PhD, Peter H. Wiernik, MD, Martin S. Tallman, MD, Robert E. Gallagher, MD

Blood (2007) 110 (11): 3167.

https://doi.org/10.1182/blood.V110.11.3167.3167

Published: 2007

Journal Articles

Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.

Bayard L. Powell, MD, Barry Moser, MD, Wendy Stock, MD, Robert E. Gallagher, MD, Cheryl L. Willman, MD, Richard M. Stone, MD, Jacob M. Rowe, MD, Steven Coutre, MD, James H. Feusner, MD, John Gregory, MD, Stephen Couban, MD, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Richard A. Larson, MD

Blood (2006) 108 (11): 566.

https://doi.org/10.1182/blood.V108.11.566.566

Published: 2006

Journal Articles

Common Gene Expression Changes in Matched Pretreatment and Relapse Samples from Eastern Cooperative Oncology Group Acute Promyelocytic Leukemia (APL) Patients Treated on the Chemotherapy (C) or All- Trans Retinoic Acid (ATRA)-Containing (A) Randomization Arms of Protocol E2491.

Qingping Cui, PhD, Haesook Kim, PhD, Peter H. Wiernik, MD, Martin S. Tallman, MD, Robert E. Gallagher, MD

Blood (2006) 108 (11): 4311.

https://doi.org/10.1182/blood.V108.11.4311.4311

Published: 2006

Journal Articles

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

Robert E. Gallagher, MD, Esther L. Schachter-Tokarz, B.A., Barry K. Moser, Ph.D., Dorie Sher, B.A., Elisabeth Paietta, Ph.D., Martin S. Tallman, M.D., Clara D. Bloomfield, M.D., Bayard L. Powell, M.D., Richard A. Larson, M.D., Frederick R. Appelbaum, M.D., Cheryl L. Willman, M.D., Richard C. Harvey, Ph.D., Wendy Stock, M.D.

Blood (2006) 108 (11): 2342.

https://doi.org/10.1182/blood.V108.11.2342.2342

Published: 2006

Journal Articles

Assessment of Minimal Residual Disease (MRD) by Qualitative RT-PCR (Q-PCR) v s Real-Time Quantitative RT-PCR (RQ-PCR) in a Phase II Study of Acute Promyelocytic Leukemia (APL).

Robert E. Gallagher, MD, Esther L. Schachter-Tokarz, AB, Dan A. Jones, MD, PhD, Elihu H. Estey, MD

Blood (2005) 106 (11): 3262.

https://doi.org/10.1182/blood.V106.11.3262.3262

Published: 2005

Journal Articles

Mutation of Cellular Retinoic Acid-Binding Protein-II (Crabp-II) Does Not Account for Resistance to All- Trans Retinoic Acid (ATRA) in Relapse Acute Promyelocytic Leukemia (APL).

Binu-John Sankoorikal, BS, Da-Cheng Zhou, MD, PhD, Peter H. Wiernik, MD, Robert E. Gallagher, MD

Blood (2004) 104 (11): 2081.

https://doi.org/10.1182/blood.V104.11.2081.2081

Published: 2004

Journal Articles

Relapse of Acute Promyelocytic Leukemia (APL) Is Associated with Increased Methylation of the Retinoic Acid Receptor-Beta2 (RARβ2) Gene Promoter.

Da-Cheng Zhou, MD, PhD, Haesook Kim, PhD, Martin S. Tallman4, MD, Robert E. Gallagher, MD

Blood (2004) 104 (11): 1124.

https://doi.org/10.1182/blood.V104.11.1124.1124

Published: 2004

Journal Articles

Identification of a Second Acute Promyelocytic Leukemia (APL) Patient with the STAT5b-RARα Fusion Gene among PML-RARα-Negative Eastern Cooperative Oncology Group (ECOG) APL Protocol Registrants.

Robert E. Gallagher, MD, Serena Mak, BA, Elisabeth Paietta, PhD, Brenda Cooper, MD, W. Christopher Ehmann, MD, Martin S. Tallman, MD

Blood (2004) 104 (11): 3005.

https://doi.org/10.1182/blood.V104.11.3005.3005

Published: 2004

NARROW

Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia

Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study

Aberrant Expression of the MLL5 , BAALC , ID1 , and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study

Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,

ΔNp73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,

Design, Synthesis and Biological Evaluation of A Boron Containing Retinoid As a Novel Therapeutic Agent for Acute Promyelocytic Leukemia

High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Increased Global Gene Promoter Methylation after Relapse (Rel) of Acute Promyelocytic Leukemia (APL) from All- trans Retinoic Acid (ATRA)-Containing Treatment Is Dissociated from Concurrent Gene Expression Changes.

Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL).

Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.

Common Gene Expression Changes in Matched Pretreatment and Relapse Samples from Eastern Cooperative Oncology Group Acute Promyelocytic Leukemia (APL) Patients Treated on the Chemotherapy (C) or All- Trans Retinoic Acid (ATRA)-Containing (A) Randomization Arms of Protocol E2491.

Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.

Assessment of Minimal Residual Disease (MRD) by Qualitative RT-PCR (Q-PCR) v s Real-Time Quantitative RT-PCR (RQ-PCR) in a Phase II Study of Acute Promyelocytic Leukemia (APL).

Mutation of Cellular Retinoic Acid-Binding Protein-II (Crabp-II) Does Not Account for Resistance to All- Trans Retinoic Acid (ATRA) in Relapse Acute Promyelocytic Leukemia (APL).

Relapse of Acute Promyelocytic Leukemia (APL) Is Associated with Increased Methylation of the Retinoic Acid Receptor-Beta2 (RARβ2) Gene Promoter.

Identification of a Second Acute Promyelocytic Leukemia (APL) Patient with the STAT5b-RARα Fusion Gene among PML-RARα-Negative Eastern Cooperative Oncology Group (ECOG) APL Protocol Registrants.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only